Christopher Ray Aker Sells 38,547 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) VP Christopher Ray Aker sold 38,547 shares of the firm's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,569.22. Following the completion of the sale, the vice president now directly owns 54,634 shares in the company, valued at approximately $68,838.84. This represents a 41.37 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Regulus Therapeutics Stock Up 3.7 %

Shares of RGLS stock traded up $0.05 during mid-day trading on Wednesday, reaching $1.27. 283,082 shares of the stock traded hands, compared to its average volume of 348,120. The company has a market cap of $83.19 million, a price-to-earnings ratio of -1.19 and a beta of 1.60. The stock's fifty day simple moving average is $1.53 and its two-hundred day simple moving average is $1.59. Regulus Therapeutics Inc. has a 1-year low of $1.08 and a 1-year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, equities research analysts anticipate that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Hedge Funds Weigh In On Regulus Therapeutics

A number of hedge funds have recently modified their holdings of RGLS. Creative Planning bought a new position in Regulus Therapeutics during the 3rd quarter worth $26,000. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at about $33,000. Jane Street Group LLC bought a new position in shares of Regulus Therapeutics during the third quarter worth about $46,000. State Street Corp lifted its stake in shares of Regulus Therapeutics by 3.5% in the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company's stock worth $1,572,000 after acquiring an additional 33,496 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in shares of Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company's stock worth $626,000 after acquiring an additional 37,480 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Wall Street Analysts Forecast Growth

RGLS has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Monday, November 11th. StockNews.com raised shares of Regulus Therapeutics to a "sell" rating in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.